Systemic Lupus Erythematosus
Conditions
Brief summary
This study is to evaluate the safety and efficacy of human umbilical cord derived mesenchymal stem cells transplantation in systemic lupus erythematosus.
Detailed description
To ensure that all patients of systemic lupus erythematosus (SLE) completed 6-months follow-up, twenty SLE patients ranging from 14 to 60 years old were enrolled in this trial. Participants matched with the inclusion criteria were allocated randomly into two groups:Human Umbilical Cord Derived Mesenchymal Stem Cells (hUC-MSCs) treated group and control group. Clinical trials are being increasingly established to investigate the therapeutic potential of these cells for SLE. The aim of the present study is to investigate safety and efficacy of vein infusion of allogeneic hUC-MSCs in patients with SLE.
Interventions
BIOLOGICALmesenchymal stem cells
SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
Sponsors
Hebei Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of SLE(Systemic lupus erythematosus) from American College of Rheumatology(ACR) according to established criteria in 1997 2. Age from 14 to 60 years 3. No serious infection or acute hemorrhage 4. Left ventricular ejection fraction (LVEF)≥ 50% 5. Both transaminase and serum creatinine level are more than twice times the upper limit of normal 6. No acute infectious diseases. 7. Understanding and willingness to sign a written informed consent document.
Exclusion criteria
Patients with SLE have to be disqualified from this study if any of the following is applicable: 1. SLE(Systemic lupus erythematosus) with severe infection. 2. Severe heart attack, liver and kidney disease following serious complications 3. Patients with allergic constitution. 4. Pregnancy and breastfeeding women. 5. Accompanied by malignant tumors or other malignant disease 6. Patients as participant in the other clinical text 7. Patients with active tuberculosis, acute sever hepatitis or infectious period of diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of Complement levels(C3 and C4) in peripheral blood | Post cell transplantation: 1, 3, 6 months | The recovery of immunologic function is evaluated by complement levels (g/L) in peripheral blood. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Erythrocyte sedimentation rate | Post cell transplantation: 1, 3, 6 months | The change of inflammation is evaluated by erythrocyte sedimentation rate. |
| C-reactive protein | Post cell transplantation: 1, 3, 6 months | C-reactive protein is an acute phase reactants. It can be moderately increased in in peripheral blood of SLE patients. |
| adverse reaction | Post cell transplantation: 1, 3, 6 months | Adverse reaction includes temperature changes(℃), the change of blood pressure(mmHg) and allergic reaction.These measurements were associated with the safety of the intervention. |
Countries
China
Contacts
Primary ContactJun Zhang, Master
Outcome results
None listed